5 Healthcare Share Prices Under Discussion Today - Starpharma, Ramsay, Mesoblast, Ansell, CLINUVEL

Summary

• The healthcare sector has been the standout performer amid the current scenario, tapping the opportunities created by the pandemic.
• The share price of Starpharma rose by 10.526% after the Company announced record FY20 results. Revenue during the period increased by 162% on pcp.
• ASX 200 listed healthcare company Ramsay demonstrated resilience during COVID-19 pandemic, FY20 Revenue up by 7.3%.
• Mesoblast is well prepared for the first US product launch; revenue during FY20 increased by 92%.
• Ansell Limited delivered resilient sales & earnings growth amid market turmoil; reported sales growth of 7.7% during FY20.
• ASX 200 listed company CLINUVEL reported 5% growth in total revenues during FY20.

The current reporting season has been challenging for many sectors with the double whammy of bushfires and COVID-19 pandemic weighing down businesses. However, the ongoing market turmoil has created an opportunity for the healthcare sector. Some of the ASX 300 listed healthcare companies have reported remarkable financials during the financial year 2020.

The impressive financial and operational performance during the period also reflected on the equity markets with some healthcare players witnessing a decent rise in their respective share prices.

Today, we will discuss 5 ASX-listed healthcare companies whose share price are up after announcing their financial results- Starpharma, Ramsay, Mesoblast, Ansell, CLINUVEL.

Starpharma Holdings Delivers Record Revenue, Share up ~10.5%

ASX-listed healthcare company Starpharma Holdings Limited (ASX:SPL) is a global leader in the development of therapeutic purpose dendrimer formulations. Starpharma is focused on women health, and its VivaGel® BV for women is based on SPL7013, which is a proprietary dendrimer.

On 27 August 2020, SPL share price stood at A$1.470, climbing by 10.526% post announcement of annual results for FY20. The shares of Starpharma delivered a positive return of 14.10% in the last three months. The market capitalisation of the SPL stood at A$495.51 million.

Let us look at the FY2020 results.

Highlights from the operational front-

• Total revenue and other income during FY20 reported at A$7.1 million, up 162% on the prior year.
• Cash position of the Company remained at A$30.1 million as of 30 June 2020.
• Net cash burn reported at A$11.2 million.
• Starpharma reported a loss of nearly A$14.7 million during the period.

Highlights from the operational front

• During FY20, the Company added three new DEP® products to its preclinical program, which has continued to generate consistent, impressive results in several cancers with limited treatment options.
• AstraZeneca initiated a Phase 1 trial for its first DEP® product, AZD0466, & triggered a US$3 million milestone payment to Starpharma.
• VivaGel® BV achieved number 1 rank in topical BV treatment across Australia.
• VivaGel® condom received EU approval; Lifestyles initiated marketing preparations for launch in Europe.
• The Therapeutic Goods Administration (TGA) licence granted to Starpharma for manufacturing of DEP® active pharmaceutical ingredient (API) in-house for clinical trial

Ramsay’s FY20 Revenue up 7.3%, Demonstrates resilience during COVID-19 pandemic

ASX 200 listed private healthcare provider, Ramsay Health Care Limited (ASX:RHC) offers high-quality services and outstanding patient care, as well as hospital management. The Company is one of the most diverse private health care companies across the world.

The share price of Ramsay was A$65.270, down by 0.518% at the end of the session on 27 August 2020. The Company has a market capitalisation of A$15.02 billion.

Let us look at the highlights of Ramsay’s YF20 results:

• Group revenue of Ramsay during FY20 rose by 7.3% to A$12.4 billion.
• Core NPAT dwindled by 43% to A$336.9 million.
• Statutory NPAT during the period down 47.9% to A$284 million.
• The Company did not declare any final dividend, fully franked interim dividend5 cents up 4.2% on pcp.
• Core earnings per share (EPS) down 44.5% to 155.9 cents
• The UK and Australia/Asia segment revenue dropped; however, Continental Europe revenue up by 14.3% to €3.9 billion.

Mesoblast’s FY20 Revenue Increased 92%, Well Prepared for First Product Launch in the US

Melbourne-headquartered regenerative medicine company Mesoblast Limited (ASX:MSB) is a frontrunner in developing innovative cellular medicines all over the world. Mesoblast has a robust emerging drug pipeline for follow-on signs with three programs currently in Phase 3 clinical studies. The Company was added in the ASX 200 index in June 2020.

Following the impressive FY20 results on 27 August 2020, MSB share price ended the day’s trade at A$5.200, up by 0.971%. The market capitalisation of the Company was A$3.01 billion. MSB shares delivered an exceptional return of 112.81% in the last six months and 36.6% return in the previous three months.

FY20 highlights (year ended 30 June 2020)

• During the fiscal year 2020, revenues rose by 92% to US$32.2 million compared to FY2019.
• MSB witnessed a 127% increase in milestone revenues from strategic partnerships to US$25.0 million.
• Commercialisation revenue from sales of TEMCELL reported at US$6.6 million, up by 32%.
• The Company has US$129.3 million cash on hand as of 30 June 2020.
• During FY20, loss after tax reduced by 13% to US$77.9 million compared with US$89.8 million for FY19.

ALSO READ: Mesoblast Share Price Goes Berserk: Investors had a Sunny Day

Highlights from the operational front-

• ODAC of the FDA was in favour that the accessible information support RYONCIL’s efficacy in SR-aGVHD.
• RYONCIL’s Biologics License Application, or BLA, is under Priority Review by the FDA with an action date of 30 September 2020, under the PDUFA.
• Post approval, Mesoblast plans for US launch of RYONCIL.

Ansell Limited Delivered Resilient Sales & Earnings Growth Amid market turmoil

ASX 200 listed world-leading superior health and safety protection provider Ansell Limited (ASX:ANN) works on the development of innovation of product and technology. Ansell operates in two primary business segments of healthcare and industrial.

On 27 August 2020, Ansell share price last traded at A$40.580, up by 0.92%. With a market capitalisation of A$5.17 billion, ANN has 128.57 million shares trading on the ASX.

Ansell Limited updated its full-year results for FY20 (ending 30 June 2020) with highlights as mentioned below:

• Sales of US$1,6 billion, up 7.7% (9.3% CC & 7.6% organic growth)
• During the period, Healthcare organic growth was 13.4%, and Industrial organic growth stood at 1.3%.
• Profit Attributable during FY20 recorded at US$158.7 million increased by 5.2% YoY and 19.0% on a CC basis as compared to FY19.
• EBIT of US$219.7 million, up 8.3% YoY and 21.0% on a CC basis. EPS up 9.2% at US121.8 cents.
• The full-year dividend increased to US50.0 cents, a rise of 7.0%.

ALSO READ: Ansell - A Star in the Pandemic-Stricken ASX Boat

CLINUVEL reported 5% growth in total revenues during FY20

A global biopharmaceutical player, CLINUVEL PHARMACEUTICALS LTD (ASX:CUV) is a leader in the field of photomedicine. The Company’s R&D has led to innovative therapies for patients with a need to treat repigmentation, photoprotection, and genetic deficiencies.

The share price of CUV was up by 4.36% on 26 August 2020. Today, the share price dropped by 4.649% to A$22.150 because of the profit booking. The market capitalisation of CUV was recorded at A$1.15 billion.

CLINUVEL PHARMACEUTICALS updated the market with its Preliminary Final Report for FY20 (year ended 30 June 2020).

• The Company reported a 5% growth in total revenues, and cash reserves grew 23%.
• Net profit before tax result reported at A$13.136 million.
• The Company declared an unfranked dividend of A$0.025 per share.
• CLINUVEL has cash and cash equivalents of approximately A$66.7 million at the end of 30 June 2020.

CLINUVEL’s critical developments in FY2020 include: